Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 billion in cash, a 38% premium over Alpine’s closing price on… Read More
— Amazon has promoted two executives to senior vice president: James Hamilton, a distinguished engineer at the company; and Drew Herdener, who leads worldwide communications. Both were previously vice presidents… Read More
The legacy of the late Microsoft co-founder Paul Allen lives on at some of Seattle’s most innovative institutions. This week GeekWire profiled the AI2 incubator, a branch of the Allen… Read More
Alpine Immune Sciences will move a potential treatment for immune conditions into human testing and support its ongoing trials for cancer thanks to around $91 million in new funding. The… Read More
Alpine Immune Sciences stock rose more than 10% Friday after the Seattle-based biotech company inked a $60 million licensing deal with pharmaceutical giant AbbVie for its lupus drug. AbbVie could… Read More
Seattle biotech company Alpine Immune Sciences is raising $17 million as part of a merger with Nivalis, a publicly-traded pharmaceutical firm in Boulder, Colo. Frazier Healthcare Partners, Alpine BioVentures, and OrbiMed Advisors… Read More
Seattle’s Alpine Immune Sciences says it has closed a $48 million Series A financing round, to fund the development of next-generation therapies that tweak the body’s immune system to fight… Read More
Seattle-based immunotherapy startup Alpine Immune Sciences has signed an exclusive licensing deal with Kite Pharma that could be worth as much as $530 million if the startup’s cancer-fighting treatments pan out.… Read More